LivaNova (NASDAQ:LIVN) Issues FY24 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $3.05-3.15 for the period, compared to the consensus estimate of $3.00. LivaNova also updated its FY 2024 guidance to 3.050-3.150 EPS.

Analyst Ratings Changes

Several research firms recently weighed in on LIVN. Barclays raised their price objective on LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a report on Monday, February 26th. Robert W. Baird boosted their price target on LivaNova from $58.00 to $66.00 and gave the stock a neutral rating in a report on Thursday. Needham & Company LLC reiterated a buy rating and issued a $72.00 price objective on shares of LivaNova in a report on Wednesday. Mizuho boosted their target price on shares of LivaNova from $75.00 to $80.00 and gave the stock a buy rating in a report on Thursday. Finally, StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a research note on Thursday, April 25th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, LivaNova has a consensus rating of Moderate Buy and an average target price of $66.20.

LivaNova Stock Up 2.0 %

NASDAQ:LIVN traded up $1.23 during trading hours on Friday, reaching $64.15. The company had a trading volume of 891,504 shares, compared to its average volume of 781,875. LivaNova has a twelve month low of $42.75 and a twelve month high of $64.36. The company has a quick ratio of 2.51, a current ratio of 3.17 and a debt-to-equity ratio of 0.50. The firm has a market cap of $3.47 billion, a price-to-earnings ratio of -106.92 and a beta of 0.92. The business’s 50-day simple moving average is $54.57 and its two-hundred day simple moving average is $50.94.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.28. The company had revenue of $294.90 million for the quarter, compared to analyst estimates of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. LivaNova’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 earnings per share. On average, equities analysts expect that LivaNova will post 3.01 earnings per share for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.